EZH2 and epithelioid sarcoma: In this context, EZH2 has emerged as an important target for the development of various inhibitors, including Tazemetostat (TAZ; Tazveric, EPZ-6438), a first-in-class potent and selective EZH2 inhibitor used in the treatment of advanced epithelioid sarcoma [11].